S. Gail Eckhardt

Affiliated with

Research Area

Biography

S. Gail Eckhardt has not added Biography.
If you are S. Gail Eckhardt and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 23	2016

Other Publications

Article	Year
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 11801542	2002
Angiogenesis inhibitors in clinical development for lung cancer. Seminars in oncology\| PubMed ID: 11894016	2002
A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 12114414	2002
A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid maligna... Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 12114416	2002
A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma. Investigational new drugs\| PubMed ID: 12201500	2002
New targets for cancer chemotherapy. Cancer chemotherapy and biological response modifiers\| PubMed ID: 12703208	2002
Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer chemotherapy and pharmacology\| PubMed ID: 12759775	2003
A Phase I and pharmacokinetic study of squalamine, an aminosterol angiogenesis inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 12855619	2003
A phase I, pharmacokinetic, and biological study of the farnesyltransferase inhibitor tipifarnib in combination with gemcitabine in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 14581347	2003
A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15475438	2004
Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15475456	2004
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 15483011	2004
A phase I and pharmacokinetic study of exisulind and docetaxel in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 15534096	2004
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors. Cancer chemotherapy and pharmacology\| PubMed ID: 15906031	2005
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. American journal of clinical oncology\| PubMed ID: 16062073	2005
Phase I, pharmacokinetic, and pharmacodynamic study of intravenously administered Ad5CMV-p53, an adenoviral vector containing the wild-type p53 gene, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 16648505	2006
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. Journal of cellular physiology\| PubMed ID: 16688779	2006
Phase II trial of bevacizumab in combination with weekly docetaxel in metastatic breast cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16707611	2006
Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16740765	2006
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinas... Molecular cancer therapeutics\| PubMed ID: 16891475	2006
Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 16983112	2006
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17000682	2006
Dynamic and modern: bringing the ethics of phase I trials up to date. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 17093287	2006
Novel targets in solid tumors: MEK inhibitors. Clinical advances in hematology & oncology : H&O\| PubMed ID: 17143253	2006
Sunitinib: from rational design to clinical efficacy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 17327610	2007
A phase I pharmacokinetic and pharmacodynamic study of s-3304, a novel matrix metalloproteinase inhibitor, in patients with advanced and refractory solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17404091	2007
A physiologically based pharmacokinetic model of docetaxel disposition: from mouse to man. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17473210	2007
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 17538178	2007
Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. American journal of clinical oncology\| PubMed ID: 17762434	2007
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 17947727	2007
Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 17971583	2007
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with ... Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 17975157	2007
Inhibition by erlotinib of primary lung adenocarcinoma at an early stage in male mice. Cancer chemotherapy and pharmacology\| PubMed ID: 18030469	2008
NMR-based metabolomics: translational application and treatment of cancer. Current opinion in molecular therapeutics\| PubMed ID: 18041668	2007
A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with... Cancer chemotherapy and pharmacology\| PubMed ID: 18058098	2008
A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies. Cancer chemotherapy and pharmacology\| PubMed ID: 18320191	2008
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18390968	2008
Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood\| PubMed ID: 18483394	2008
A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18579665	2008
A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy. Investigational new drugs\| PubMed ID: 18618082	2009
Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 18640940	2008
Patient-reported outcomes as a component of the primary endpoint in a double-blind, placebo-controlled trial in advanced pancreatic cancer. Journal of pain and symptom management\| PubMed ID: 18723314	2009
Targeted manipulation of apoptosis in cancer treatment. The Lancet. Oncology\| PubMed ID: 18760670	2008
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Molecular cancer therapeutics\| PubMed ID: 19074845	2008
KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 19124802	2009
Clinical applications of metabolomics in oncology: a review. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 19147747	2009
Vorinostat and bortezomib exert synergistic antiproliferative and proapoptotic effects in colon cancer cell models. Molecular cancer therapeutics\| PubMed ID: 19174560	2009
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation... American journal of clinical oncology\| PubMed ID: 19307945	2009
KRAS mutations and susceptibility to cetuximab and panitumumab in colorectal cancer. Cancer journal (Sudbury, Mass.)\| PubMed ID: 19390304	2009
Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 19401345	2009
Population pharmacokinetic model of PI-88, a heparanase inhibitor. Cancer chemotherapy and pharmacology\| PubMed ID: 19633850	2010
Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 19652058	2009
Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells. British journal of pharmacology\| PubMed ID: 19663881	2009
Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Molecular cancer therapeutics\| PubMed ID: 19755510	2009
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 20048182	2010
Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid ... Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20068101	2010
A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer. Investigational new drugs\| PubMed ID: 20084425	2011
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. International journal of radiation oncology, biology, physics\| PubMed ID: 20133082	2010
BRCA in breast cancer: from risk assessment to therapeutic prediction. Drug news & perspectives\| PubMed ID: 20140280	2009
A phase I safety and pharmacokinetic study of the death receptor 5 agonistic antibody PRO95780 in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20145186	2010
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20179232	2010
A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20371689	2010
Assessment of the in vivo antitumor effects of ENMD-2076, a novel multitargeted kinase inhibitor, against primary and cell line-derived human colorectal cancer xenograft models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20406842	2010
Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 20458040	2010
Novel agents in the treatment of metastatic colorectal cancer. Cancer journal (Sudbury, Mass.)\| PubMed ID: 20526106	2010
Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20530704	2010
Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20682712	2010
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20810384	2010
Barriers to enrollment of elderly adults in early-phase cancer clinical trials. Journal of oncology practice / American Society of Clinical Oncology\| PubMed ID: 20856765	2008
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Molecular cancer therapeutics\| PubMed ID: 20923857	2010
The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer model... Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 20943761	2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21131552	2011
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 21220471	2011
Documenting the natural history of patients with resected stage II adenocarcinoma of the colon after random assignment to adjuvant treatment with edrecolomab or observation: results from CAL... Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 21747085	2011
Preclinical activity of the rational combination of selumetinib (AZD6244) in combination with vorinostat in KRAS-mutant colorectal cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22173548	2012
Phase 1 study of rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22338014	2012
Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152). Journal of medicinal chemistry\| PubMed ID: 22413863	2012
JAK2 inhibition for the treatment of hematologic and solid malignancies. Expert opinion on investigational drugs\| PubMed ID: 22493978	2012
Patient-derived tumour xenografts as models for oncology drug development. Nature reviews. Clinical oncology\| PubMed ID: 22508028	2012
Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22553375	2012
ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature chemical biology\| PubMed ID: 22660439	2012
A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22693357	2012
Dogs are more sensitive to antagonists of inhibitor of apoptosis proteins than rats and humans: a translational toxicokinetic/toxicodynamic analysis. Toxicological sciences : an official journal of the Society of Toxicology\| PubMed ID: 22843607	2012
Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with erlotinib. Investigational new drugs\| PubMed ID: 23135778	2013
Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23136197	2013
First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23403628	2013
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23434733	2013
Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PloS one\| PubMed ID: 23520486	2013
Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Frontiers in pharmacology\| PubMed ID: 23524533	2013
Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in pharmacology\| PubMed ID: 23543898	2013
MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of clinical investigation\| PubMed ID: 23585477	2013
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 23610116	2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23757356	2013
Accelerated approval and breakthrough therapy designation: oncology drug development on speed? Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23833307	2013
AZD1480: a phase I study of a novel JAK2 inhibitor in solid tumors. The oncologist\| PubMed ID: 23847256	2013
Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24045180	2013
From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. Journal of the National Cancer Institute\| PubMed ID: 24052618	2013
Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. Pharmacology & therapeutics\| PubMed ID: 24362082	2014
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 24493827	2014
Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. Therapeutic advances in medical oncology\| PubMed ID: 24790649	2014
Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. Journal of clinical oncology : official journal of the American Society of Clinical Oncology\| PubMed ID: 25002720	2014
Distress among caregivers of phase I trial participants: a cross-sectional study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer\| PubMed ID: 25120010	2014
Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Molecular cancer therapeutics\| PubMed ID: 25376610	2015
Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. PloS one\| PubMed ID: 25401499	2014
Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25501576	2015
p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Molecular cancer therapeutics\| PubMed ID: 25758253	2015
The changing landscape of phase I trials in oncology. American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting\| PubMed ID: 25993134	2015
Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Frontiers in pharmacology\| PubMed ID: 26136684	2015
Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget\| PubMed ID: 26439693	2015
The changing landscape of phase I trials in oncology. Nature reviews. Clinical oncology\| PubMed ID: 26552953	2016
An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC genomics\| PubMed ID: 26681397	2015
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Investigational new drugs\| PubMed ID: 26715573	2016
Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 26831715	2016
The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget\| PubMed ID: 27070088	2016
Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget\| PubMed ID: 27385211	2016
Metabolic Imaging to Assess Treatment Response to Cytotoxic and Cytostatic Agents. Frontiers in oncology\| PubMed ID: 27471678	2016